| Primary | Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR) | mITT population; (composite incidence) | mITT population, based on available data | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Incidence of All-cause Mortality or MI | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of All-cause Mortality | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of MI | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of IDR | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of Stent Thrombosis | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of Stroke | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of All-cause Mortality | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 1 year post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis] | mITT population A patient could have multiple procedural events. | mITT population, based on available data | Posted | | Number | | participants | | During index PCI | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of GUSTO Severe / Life-threatening | Major bleeding (non-CABG-related) - Safety population | | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major | Major bleeding (non-CABG-related) - Safety population | | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of ACUITY Major Bleeding | Major bleeding (non-CABG-related) - Safety population | | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm | Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm. | | Posted | | Number | | participants | | randomization through 48 hours post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of All-cause Mortality, MI, or IDR | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 30 days post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of All-cause Mortality or MI | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 30 days post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of All-cause Mortality | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 30 days post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of MI | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 30 days post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of IDR | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 30 days post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of Stent Thrombosis | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 30 days post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |
| Secondary | Incidence of Stroke | | mITT population, based on available data | Posted | | Number | | participants | | randomization through 30 days post randomization | | | | ID | Title | Description |
|---|
| OG000 | Cangrelor | cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | | OG001 | Clopidogrel | placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion |
| |